---
title: "CAF最强汇总来啦"
date: 2023-04-23T00:20:22Z
draft: ["false"]
tags: [
  "fetched",
  "生信人"
]
categories: ["Acdemic"]
---
CAF最强汇总来啦 by 生信人
------
<div><section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><p>April</p></section></section></section><section><section powered-by="xiumi.us"><p><strong>概普生物 <span>2023</span></strong></p></section></section></section></section></section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><p><strong>NEW TOPIC</strong></p></section></section></section></section></section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><p><strong>星标“生信人”精彩不错过</strong></p></section></section></section><section><section powered-by="xiumi.us"><section><img data-ratio="1.1363636363636365" data-src="https://mmbiz.qpic.cn/mmbiz_png/WpEKj19OcpKuGlT6OThKmJWlMbuQO5sogScOEEu7QXmFh7IKtwiba3XEGSqyvKcOIdnOT2WicjoAvvPeUGMpuSVA/640?wx_fmt=png" data-w="22" width="100%" src="https://mmbiz.qpic.cn/mmbiz_png/WpEKj19OcpKuGlT6OThKmJWlMbuQO5sogScOEEu7QXmFh7IKtwiba3XEGSqyvKcOIdnOT2WicjoAvvPeUGMpuSVA/640?wx_fmt=png"></section></section></section></section></section></section><p powered-by="xiumi.us"><br></p><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><p>“最近几年关于癌症相关成纤维细胞（CAF）的研究越来越多，可以说是一个热门话题。今天小编来给大家总结一些<strong><span>CAF生信研究思路</span></strong>，感兴趣的小伙伴不要错过哦！”</p></section></section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><p><strong><span>异质肿瘤微环境(TME)</span></strong>是肿瘤的重要组成部分，它们与恶性细胞相互作用，并形成癌症特征。TME中存在不同类型的非恶性细胞，主要包括成纤维细胞、免疫细胞和内皮细胞。TME在癌症中有着不可或缺的作用，如肿瘤进展、治疗耐药、血管生成诱导和转移。</p><p><br></p><p>成纤维细胞是TME的主要成分，而<strong><span>癌症相关成纤维细胞(CAF)</span></strong>在癌症中发挥着多种作用。除了直接与恶性上皮细胞相互作用外，CAF还可促进血管生成、招募髓系细胞，以及T细胞的免疫抑制。因此，<span>CAF通过与其他TME成分相互作用，在塑造TME中发挥关键作用，显示出它们作为预后因素和治疗靶点的潜在价值。</span>另一方面，由于其异质性和可塑性，CAF对TME的调节是多样和模糊的。</p><p><br></p><p>近年来，<strong><span>scRNA-seq技术</span></strong>为研究细胞状态的波动和细胞可塑性的强度提供了机会。已经在多种癌症中描绘了癌细胞和TME，揭示了在单细胞分辨率下具有不同成分的癌症样本的异质性，并暗示它们可能参与了癌症的生物学功能。</p></section></section></section></section></section></section><p powered-by="xiumi.us"><br></p><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><p><strong>01</strong></p></section></section><section><section powered-by="xiumi.us"><section><p><strong>CAF异质性</strong></p></section></section></section></section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><p>Part One</p></section></section><section><section powered-by="xiumi.us"><section><svg viewbox="0 0 1 1"></svg></section></section></section></section><p powered-by="xiumi.us"><br></p><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><p><br></p><p>CAF的异质性包括它们的<span>来源、转录组和功能</span>等不同方面。最近的研究显示，TME中存在转录上不同的CAF亚型，主要起源于<strong><span>常驻成纤维细胞</span></strong>。广泛报道的亚型包括富含ECM转录本的肌成纤维细胞CAF(MyCAF)；富含炎症反应和生长因子转录本的炎性CAF(iCAF)；富含MHC II转录本的抗原提呈CAF(apCAF)。以及其他亚群，包括富含参与血管发育的转录本的血管CAF(vCAF)；表达与EMT相关的转录本的EMT样CAF(eCAF)；以及调节涉及脂质代谢的基因转录本的脂纤维母细胞(lCAF)等等，<span>CAF亚群的数量和命名方式到目前为止尚未达成共识</span>。</p><p><br></p><p>本月最新发表在<strong><span>HEPATOLOGY（IF：17+）</span></strong>的综述归纳整理了scRNA-seq鉴定人和小鼠CAF亚型和标志物。</p></section><section powered-by="xiumi.us"><p><br></p></section><section powered-by="xiumi.us"><section><img data-ratio="1.4292803970223324" data-src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjX2Da8CaaibAr4UZCVCLQdFIEqgDb50ZxBZtd4gNLyBxwOGCI42e4MtpYByvPHTt3Noekgh7QqZPjw/640?wx_fmt=png" data-w="806" width="100%" src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjX2Da8CaaibAr4UZCVCLQdFIEqgDb50ZxBZtd4gNLyBxwOGCI42e4MtpYByvPHTt3Noekgh7QqZPjw/640?wx_fmt=png"></section></section><section powered-by="xiumi.us"><p>图1 人CAF亚型和标志物</p></section><section powered-by="xiumi.us"><p><br></p></section><section powered-by="xiumi.us"><section><img data-ratio="0.7237977805178791" data-src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjX2Da8CaaibAr4UZCVCLQdFI7f83ZKBD9yHFicKFBRW8E4lQZqbFFetlrOOSVY0XwaLaYeJ3aUqYU9Q/640?wx_fmt=png" data-w="811" width="100%" src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjX2Da8CaaibAr4UZCVCLQdFI7f83ZKBD9yHFicKFBRW8E4lQZqbFFetlrOOSVY0XwaLaYeJ3aUqYU9Q/640?wx_fmt=png"></section></section><section powered-by="xiumi.us"><p>图2 小鼠CAF亚型和标志物</p></section><section powered-by="xiumi.us"><p><br></p></section><section powered-by="xiumi.us"><p>21年发表在<strong><span>cancer cell</span></strong>的文章（Three subtypes of lung cancer fibroblasts definedistinct therapeutic paradigms）中，作者<span>根据CAF的异质性在非小细胞肺癌(NSCLC)中确定了三种功能亚型</span>。CAF之间的这些功能差异是由其内在的TGF-β信号控制的，TGF-β信号抑制了HGF和 FGF7的表达。这种CAF功能分类与患者对靶向治疗的临床反应相关，也与肿瘤免疫微环境相关。</p></section><section powered-by="xiumi.us"><p><br></p></section><section powered-by="xiumi.us"><section><img data-ratio="0.8966480446927374" data-src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjX2Da8CaaibAr4UZCVCLQdFIWbjJzic275FEPZ8PuAiaFY51s4x2zWl43AN3uxnkWU3Fh0S4S11XogSQ/640?wx_fmt=png" data-w="358" width="100%" src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjX2Da8CaaibAr4UZCVCLQdFIWbjJzic275FEPZ8PuAiaFY51s4x2zWl43AN3uxnkWU3Fh0S4S11XogSQ/640?wx_fmt=png"></section></section><section powered-by="xiumi.us"><p>图3  NSCLC的三种亚型</p></section><section powered-by="xiumi.us"><p><br></p></section><section powered-by="xiumi.us"><p>22年11月份发表<strong><span>nature communications</span></strong>了一篇文章，题目是“Pan-cancer single-cell analysis reveals the heterogeneity and plasticity of cancer-associated fibroblasts in the tumor microenvironment”（之前小编也解读过）。文章对10种实体瘤的226个样本进行泛癌分析，以单细胞分辨率描述TME，<span>说明异质性CAF的共性/可塑性。</span>在这篇文章中，作者主要报道了六种成纤维细胞亚型，分别是三种主要的CAF亚型：癌症相关肌成纤维细胞(CAFmyo)、炎性CAF(CAFinfla)和成脂CAF(CAFadi)；以及三种次要的亚型：内皮细胞到间充质转化CAF(CAFEndMT)、外周神经样CAF(CAFPN)和抗原提呈CAF(CAFap)。主要CAF类型可能来源于局部正常成纤维细胞的激活，与其他细胞表现出明显的相互作用，并与免疫治疗的预后有关。次要CAF来自内皮细胞，周围神经和巨噬细胞。</p></section><section powered-by="xiumi.us"><p><br></p></section><section powered-by="xiumi.us"><section><img data-ratio="0.45306859205776173" data-src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjX2Da8CaaibAr4UZCVCLQdFIMF6unH5EsOu9zPL4lpmfWEWL20lgjAZ4nBa1fojc6tPMW0KZfeMRNg/640?wx_fmt=png" data-w="554" width="100%" src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjX2Da8CaaibAr4UZCVCLQdFIMF6unH5EsOu9zPL4lpmfWEWL20lgjAZ4nBa1fojc6tPMW0KZfeMRNg/640?wx_fmt=png"></section></section><section powered-by="xiumi.us"><p>图4 CAF的来源及作用机制</p></section><section powered-by="xiumi.us"><p><br></p></section><section powered-by="xiumi.us"><p>由于所有CAF亚群在同一肿瘤中共存，研究它们在肿瘤发生过程中的功能以及它们的可塑性仍然是目前的热点。事实上，研究特定CAF亚群的功能作用仍然非常困难，这主要是由于缺乏特定的CAF细胞系，以及在体外分离和维持它们比较困难。</p><p><br></p><p>很多肿瘤类型都会转移到肝脏，肝脏是最常见的转移器官部位。21年发表的文章（Tumor restriction by type I collagen opposes tumor-promoting effects of cancer-associated fibroblasts）指出，<span>肝星状细胞（HSC）是CAF的主要来源之一</span>（图5）。此外，在同一肿瘤中存在myCAF和iCAF，两者都来自于相同的前体细胞类型的HSCs，这表明存在可塑性程序，有待在炎性胆管癌(iCCA)的实验模型中进一步研究。此外，显示混合和中间表型的转录杂交CAF亚群的存在指向表型的转变，这说明<span>CAF能够快速适应肿瘤和不断演变的TME的需要</span>。</p></section><section powered-by="xiumi.us"><p><br></p></section><section powered-by="xiumi.us"><section><img data-ratio="0.3897058823529412" data-src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjX2Da8CaaibAr4UZCVCLQdFILcNO7ks1L8sqWLkjU8Lng9cGhCWic29AEI0cfEPDVyCjV9l7mHYT0Jg/640?wx_fmt=png" data-w="408" width="100%" src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjX2Da8CaaibAr4UZCVCLQdFILcNO7ks1L8sqWLkjU8Lng9cGhCWic29AEI0cfEPDVyCjV9l7mHYT0Jg/640?wx_fmt=png"></section></section><section powered-by="xiumi.us"><p>图5 CAF来源及作用</p></section><section powered-by="xiumi.us"><p><br></p></section></section></section><p powered-by="xiumi.us"><br></p><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><p><strong>02</strong></p></section></section><section><section powered-by="xiumi.us"><section><p><strong>CAF促进肿瘤的发展和侵袭</strong></p></section></section></section></section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><p>Part Two</p></section></section><section><section powered-by="xiumi.us"><section><svg viewbox="0 0 1 1"></svg></section></section></section></section><p powered-by="xiumi.us"><br></p><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><p><br></p><p>Paula Cantallops Vilà等人的文章总结了CAF在胆管癌（CCA）中的多种作用。在胆管癌变过程中，CAF主要通过分泌细胞因子和生长因子、细胞外小泡和ECM蛋白与TME中的肿瘤细胞和其他基质细胞发生串扰。在与肿瘤细胞-CAF串扰有关的众多分子中，生长因子是CAF分泌组的关键成分（图6）。肝素结合表皮生长因子(HB-EGF)由间质肌成纤维细胞表达，并已知在CCA细胞中诱导EGFR激活，从而通过旁分泌信号促进肿瘤细胞的迁移和侵袭。在HB-EGF刺激下，CCA肿瘤细胞产生TGF-β1，诱导肌成纤维细胞表达HB-EGF1，导致持续的反馈环，维持CCA的进展。人CCA细胞和HSC的体外共培养研究表明，CCA细胞增加了HSC分泌的EGF和TGF-β1。</p></section><section powered-by="xiumi.us"><p><br></p></section><section powered-by="xiumi.us"><section><img data-ratio="0.7768518518518519" data-src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjX2Da8CaaibAr4UZCVCLQdFIrwogCNelneoJFeL06dylP1P0AvFwgQAd7yggibQEf6lt5Q1tYJd2yeA/640?wx_fmt=png" data-w="1080" width="100%" src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjX2Da8CaaibAr4UZCVCLQdFIrwogCNelneoJFeL06dylP1P0AvFwgQAd7yggibQEf6lt5Q1tYJd2yeA/640?wx_fmt=png"></section></section><section powered-by="xiumi.us"><p>图6 CCA中肿瘤细胞-CAF串扰</p></section><section powered-by="xiumi.us"><p><br></p></section><section powered-by="xiumi.us"><section><img data-ratio="0.8411122144985105" data-src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjX2Da8CaaibAr4UZCVCLQdFIgWNicBSFEe7SaZ2dN6b0WuYfXOA2O9uMlI1KZpRsgr0BpWGwtvyRPibA/640?wx_fmt=png" data-w="1007" width="100%" src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjX2Da8CaaibAr4UZCVCLQdFIgWNicBSFEe7SaZ2dN6b0WuYfXOA2O9uMlI1KZpRsgr0BpWGwtvyRPibA/640?wx_fmt=png"></section></section><section powered-by="xiumi.us"><p>图7 CAF在胆管癌中的作用</p></section><section powered-by="xiumi.us"><p>来源于CAF的外泌体也被证明参与胆管癌变。由于CAF-肿瘤细胞的串扰是双向的，CCA肿瘤细胞也会产生影响CAF的外泌体，促进CAF的存活和扩张。事实上，已经描述了癌症来源的外泌体可能会刺激骨髓间充质干细胞(BMSCs)分化为CAF，这有助于细胞外基质的形成，并最终促进CCA的生长。</p><p>21年发表在Cancer Cell Internationa杂志的一项研究<span>（Downregulation of tumor‐derived exosomal miR-34c induces cancer‐associated fbroblast activation to promote cholangiocarcinoma progress）</span>发现<span>CCA细胞来源的外泌体中发现的miR-34c，通过直接靶向WNT1来抑制CAF的激活。</span>因此，在CCA中，miR-34c在外泌体中的表达减少，并促进肿瘤的进展（图8）。</p></section><section powered-by="xiumi.us"><p><br></p></section><section powered-by="xiumi.us"><section><img data-ratio="0.7996389891696751" data-src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjX2Da8CaaibAr4UZCVCLQdFIP2NhX7Mptarr444kd5TCsNucMIGgG1hiaB5y7Y6Gliao2WNSceJlOcbA/640?wx_fmt=png" data-w="554" width="100%" src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjX2Da8CaaibAr4UZCVCLQdFIP2NhX7Mptarr444kd5TCsNucMIGgG1hiaB5y7Y6Gliao2WNSceJlOcbA/640?wx_fmt=png"></section></section><section powered-by="xiumi.us"><p>图8 癌细胞分泌的外泌体调节成纤维细胞的激活</p></section><section powered-by="xiumi.us"><p><br></p></section></section></section><p powered-by="xiumi.us"><br></p><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><p><strong>03</strong></p></section></section></section><section><section powered-by="xiumi.us"><section><p><strong>CAF在免疫调节和免疫抑制中的作用</strong></p></section></section></section></section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><p>Part Three</p></section></section><section><section powered-by="xiumi.us"><section><svg viewbox="0 0 1 1"></svg></section></section></section></section><p powered-by="xiumi.us"><br></p><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><p><br></p><p><span>免疫抑制是肿瘤细胞用来逃避免疫监视的策略之一，允许它们增殖和扩张。</span>为了逃避免疫系统的清除，肿瘤细胞采用不同的策略，包括失去抗原性、失去免疫原性和与包括CAF在内的基质细胞串扰，以创造一个免疫抑制的微环境。CAF已被证明通过分泌免疫抑制因子、促炎分子和趋化因子来调节抗肿瘤反应，这些免疫抑制因子和趋化因子与免疫系统相互作用，并在一定程度上导致免疫检查点阻断治疗在几种肿瘤中的疗效受限。</p><p><br></p><p>在调节先天免疫反应的促炎细胞因子中，CCA中的CAF分泌IL-8、MIF、CCL2和IL-13。其中IL-13在CCA的巨噬细胞侵袭和肿瘤进展中起作用。此外，CAF通过分泌IL-6、CXCL12和巨噬细胞集落刺激因子(MCSF)支持TAMs的M2极化。</p><p><br></p><p>CAF的FAP表达对STAT3的激活，CCL2的产生和骨髓来源抑制细胞（MDSCs）的招募至关重要，MDSCs是一种强大的免疫抑制细胞类型，被描述为通过抑制T细胞和NK细胞抗肿瘤功能来促进肿瘤进展。在成纤维细胞中的敲除FAP减少了肿瘤的生长、MDSC的浸润和血管生成，因此，CAF来源的FAP的特异性靶向可能代表了iCCA的一种新的治疗策略。</p><p><br></p><p>22年<strong><span>nature communications</span></strong>的文章（Single-cell and spatial analysis reveal interaction of</p><p>FAP+fibroblasts and SPP1+ macrophages in colorectal cancer）作者通过单细胞数据分析，证明了肿瘤特异性 FAP+成纤维细胞和 SPP1+ 巨噬细胞呈正相关，并通过免疫荧光染色和空间转录组学验证了它们之间空间定位紧密（图9）。这种相互作用可能受到chemerin, TGF-β, 和 interleukin-1的调节，刺激免疫排斥的结缔组织结构的形成并限制T细胞的浸润。此外，高 FAP 或 SPP1 表达的患者抗 PD-L1 治疗中收益较差。<span>作者通过破坏 FAP+成纤维细胞和SPP1+巨噬细胞的相互作用来改善免疫治疗，从而提供了一种潜在的治疗策略</span>。</p></section><section powered-by="xiumi.us"><p><br></p></section><section powered-by="xiumi.us"><section><img data-ratio="1.4324894514767932" data-src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjX2Da8CaaibAr4UZCVCLQdFIyAuVfflnaYDW4GUtZ1OCbPDeO4Wu4rmgfuNw9NRqeJ2nnOJTY1G4Gw/640?wx_fmt=png" data-w="474" width="100%" src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjX2Da8CaaibAr4UZCVCLQdFIyAuVfflnaYDW4GUtZ1OCbPDeO4Wu4rmgfuNw9NRqeJ2nnOJTY1G4Gw/640?wx_fmt=png"></section></section><section powered-by="xiumi.us"><p>图9 FAP+成纤维细胞和SPP1+巨噬细胞的高渗透与患者的生存和免疫耐药相关</p></section><section powered-by="xiumi.us"><p><br></p></section><section powered-by="xiumi.us"><p>上月发表在<strong><span>NATURE REVIEWS CANCER</span></strong>的综述（The advent of immune stimulating CAFs in cancer）指出，目前发现了CAF的各种免疫刺激状态(图10)。<strong><span>CAF的免疫功能并不总是有利于肿瘤的</span></strong>。首先，几项临床研究发现，特定的CAF表型与存活率呈正相关，这可能解释了靶向CAF的治疗药物在临床试验中失败的原因。目前的工作进一步强调了已知的myCAF–iCAF之外的CAF的存在，并表明传统的分类方案本身可能并不总是关于CAF的免疫结果的信息。有证据表明，T细胞丰度的增加至少部分是通过免疫刺激性CAF、ECM和分泌组诱导的。</p></section><section powered-by="xiumi.us"><p><br></p></section><section powered-by="xiumi.us"><section><img data-ratio="0.4963898916967509" data-src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjX2Da8CaaibAr4UZCVCLQdFIia0yXSpK0L09ialG1Rms53aiaNkb1Tzdn1IgM13lc9FGTRRJ4Tkichv92A/640?wx_fmt=png" data-w="554" width="100%" src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjX2Da8CaaibAr4UZCVCLQdFIia0yXSpK0L09ialG1Rms53aiaNkb1Tzdn1IgM13lc9FGTRRJ4Tkichv92A/640?wx_fmt=png"></section></section><section powered-by="xiumi.us"><p>图10 免疫刺激癌症相关成纤维细胞</p></section><section powered-by="xiumi.us"><p><br></p></section><section powered-by="xiumi.us"><p>其中抗原呈递CAFs(apCAF)表达MHC II可以在体外向T细胞递呈抗原，诱导naive T细胞向Treg细胞分化。肺癌中的apCAF数量在所有CAF中所占比例不到10%。apCAF通常表达CD74，这是MHC II类分子从粗面内质网运输到晚期内体所必需的。还表达一组重叠的间皮和上皮基因，如CLU、SLPI、IL-6以及趋化因子CXCL9和CXCL10。</p><p><br></p><p>MHC-II类阳性的apCAF在体外直接将抗原递送给效应的CD4+T细胞。原代肺CAF可以在没有经典共刺激分子的情况下激活癌症抗原特异性效应细胞CD4+T细胞。在体内，CAF中MHC II的缺失特异性地导致了CD4+T细胞代谢适合性的丧失以及伴随而来的肿瘤负荷的增加。乳腺癌apCAF在微环境中干扰素增加的情况下扩大TGF β的阻断，产生T细胞趋化物质，并与患者生存呈正相关，提示有免疫刺激作用。相反，胰腺癌小鼠apCAF在培养中诱导naive T细胞分化为Treg细胞，并与FOXP3+细胞在影像分析中呈正相关。</p><p><br></p><p><span>到目前为止进行的少数几项有针对性的研究都同意apCAF改变肿瘤免疫，</span>这种影响超出了抗原呈递的范围。免疫学结果可能是组织特异性的，肺癌和乳腺癌的apCAF属于免疫刺激性CAF的保护伞，而胰腺癌CAF重叠免疫抑制状态。然而，它也可以由apCAF对效应T细胞和Treg细胞的平行、联合或相互冲突的作用所决定。</p></section><section powered-by="xiumi.us"><p><br></p></section></section></section><p powered-by="xiumi.us"><br></p><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><p><strong>04</strong></p></section></section><section><section powered-by="xiumi.us"><section><p><strong>CAF与血管生成</strong></p></section></section></section></section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><p>Part Four</p></section></section><section><section powered-by="xiumi.us"><section><svg viewbox="0 0 1 1"></svg></section></section></section></section><p powered-by="xiumi.us"><br></p><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><p><br></p><p><strong><span>新生血管生成是指从原有的血管开始形成新的血管</span></strong>，这是多种癌症的共同特征，血管生成增加与生存率下降相关。肿瘤也需要发展新的血管网络来支持自身的生长，并为肿瘤细胞提供所需的营养物质和氧气。然而，由于肿瘤细胞的高增殖率，新生成的血管呈现不成熟的表型，并伴有较低的功能，从而导致缺氧，增加肿瘤细胞侵袭和减少免疫细胞的渗透。虽然内皮细胞和肿瘤相关内皮细胞（TEC）是参与肿瘤新生血管生成的主要细胞类型，但CAF在这一过程中的作用开始逐渐被了解阐明。</p><p><br></p><p>19年发表在<strong><span>JOURNALOF HEPATOLOGY</span></strong>上的文章（Platelet-derived growth factor-D enables liver myofibroblasts to promote tumor lymphangiogenesis in cholangiocarcinoma）指出与肿瘤相关的新生血管生成主要涉及淋巴管而不是血管腔。CCA以血管内皮生长因子(VEGFs)和血管内皮生长因子受体(VEGFRs)的表达为特征，近年来被认为是CCA中肿瘤间质中血管内皮生长因子的主要细胞来源。肿瘤导管释放的PDGF-D吸引并激活肝成纤维细胞分泌VEGF-C/VEGF-A。淋巴管生成和淋巴侵袭是由肝肌成纤维细胞释放的VEGF-A/ c驱动的。体内靶向肝肌成纤维细胞抑制肿瘤相关淋巴管生成和淋巴结转移（图11，12）。</p></section><section powered-by="xiumi.us"><p><br></p></section><section powered-by="xiumi.us"><section><img data-ratio="0.7015503875968992" data-src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjX2Da8CaaibAr4UZCVCLQdFItiazB8DOhQmQZKpzTLSmSRvegc9x9qvKtkYs2qJXImg3G9ibyIPBCfxQ/640?wx_fmt=png" data-w="258" width="100%" src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjX2Da8CaaibAr4UZCVCLQdFItiazB8DOhQmQZKpzTLSmSRvegc9x9qvKtkYs2qJXImg3G9ibyIPBCfxQ/640?wx_fmt=png"></section></section><section powered-by="xiumi.us"><p>图11 </p></section><section powered-by="xiumi.us"><p><br></p></section><section powered-by="xiumi.us"><section><img data-ratio="0.5605700712589073" data-src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjX2Da8CaaibAr4UZCVCLQdFILqGGEScZD1ficqFeoAvfdKyL3wp98FPYBNcARoP4icG3qZz0hGPnusWw/640?wx_fmt=png" data-w="421" width="100%" src="https://mmbiz.qpic.cn/mmbiz_png/N3X4LBoaQjX2Da8CaaibAr4UZCVCLQdFILqGGEScZD1ficqFeoAvfdKyL3wp98FPYBNcARoP4icG3qZz0hGPnusWw/640?wx_fmt=png"></section></section><section powered-by="xiumi.us"><p>图12 在PDGF-D刺激下，肝成纤维细胞发挥多种淋巴管生成功能</p></section><section powered-by="xiumi.us"><p><br></p></section><section powered-by="xiumi.us"><p>由于很多癌症的免疫治疗应答率较低，治疗后复发率高，针对包括基质细胞在内的替代靶点的治疗方法受到越来越多的关注。CAFs已成为改进抗癌治疗的治疗靶点。目前的研究<span>旨在删除免疫抑制的CAF，将它们重新编程到正常状态，或者靶向CAF衍生的免疫抑制因子</span>。在过去的几年里，靶向CAF的新方法已经开始出现，但由于CAF的可塑性和CAF在肿瘤利基内维持的复杂的相互作用网络，<span>在临床上几乎没有成功</span>。虽然scRNA-Seq技术已经帮助破译了CAF的表型异质性，但仍然缺乏区分CAF亚型的特异和可靠的标记。此外，还需要优化组织学技术和抗体，以期在临床实践中快速检测特定的CAF亚群。</p><p><br></p><p>希望小编的这些总结可以帮助到各位的嗑盐之路！</p></section></section></section><p powered-by="xiumi.us"><br></p><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><svg viewbox="0 0 1 1"></svg></section></section></section><section><section powered-by="xiumi.us"><p><strong>往期热点 </strong><span><strong><span>（点击标题跳转）</span></strong></span></p></section></section></section></section></section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><p><strong>01</strong></p></section></section><section><a title="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651214528&amp;idx=2&amp;sn=0b81200f628c17669485151ade52925d&amp;chksm=8b5f55afbc28dcb9c93ff31400a893604301943ddfb50d6c8406eb8737bb6d9f6a7fb5f57c71&amp;token=1389154756&amp;lang=zh_CN&amp;scene=21#wechat_redirect" formlinkparm='"https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651214528&amp;idx=2&amp;sn=0b81200f628c17669485151ade52925d&amp;chksm=8b5f55afbc28dcb9c93ff31400a893604301943ddfb50d6c8406eb8737bb6d9f6a7fb5f57c71&amp;token=1389154756&amp;lang=zh_CN&amp;scene=21#wechat_redirect"' href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651214528&amp;idx=2&amp;sn=0b81200f628c17669485151ade52925d&amp;chksm=8b5f55afbc28dcb9c93ff31400a893604301943ddfb50d6c8406eb8737bb6d9f6a7fb5f57c71&amp;token=1389154756&amp;lang=zh_CN&amp;scene=21#wechat_redirect" target="_blank" rel="noopener noreferrer" powered-by="xiumi.us" data-linktype="2"><section><p><strong>线粒体质量控制</strong></p></section></a></section></section></section></section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><p><strong>02</strong></p></section></section><section><a title="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651214712&amp;idx=1&amp;sn=09dd54fe9f077c3a25cfc3b7b40b339f&amp;chksm=8b5f5417bc28dd0158bffa8c928296428f31c897abba4b12daaeae05f655a47889dec37ff6ab&amp;token=1389154756&amp;lang=zh_CN&amp;scene=21#wechat_redirect" formlinkparm='"https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651214712&amp;idx=1&amp;sn=09dd54fe9f077c3a25cfc3b7b40b339f&amp;chksm=8b5f5417bc28dd0158bffa8c928296428f31c897abba4b12daaeae05f655a47889dec37ff6ab&amp;token=1389154756&amp;lang=zh_CN&amp;scene=21#wechat_redirect"' href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651214712&amp;idx=1&amp;sn=09dd54fe9f077c3a25cfc3b7b40b339f&amp;chksm=8b5f5417bc28dd0158bffa8c928296428f31c897abba4b12daaeae05f655a47889dec37ff6ab&amp;token=1389154756&amp;lang=zh_CN&amp;scene=21#wechat_redirect" target="_blank" rel="noopener noreferrer" powered-by="xiumi.us" data-linktype="2"><section><p><strong>孟德尔随机化</strong></p></section></a></section></section></section></section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><p><strong>03</strong></p></section></section><section><a title="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651213782&amp;idx=1&amp;sn=6fab7af7962d65694a35e3f52abf39e4&amp;chksm=8b5f48b9bc28c1afbd0ec13b9eae9d8e08bf1a3c852d72e4c0c6420394fa362b1678d1a818ec&amp;token=1389154756&amp;lang=zh_CN&amp;scene=21#wechat_redirect" formlinkparm='"https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651213782&amp;idx=1&amp;sn=6fab7af7962d65694a35e3f52abf39e4&amp;chksm=8b5f48b9bc28c1afbd0ec13b9eae9d8e08bf1a3c852d72e4c0c6420394fa362b1678d1a818ec&amp;token=1389154756&amp;lang=zh_CN&amp;scene=21#wechat_redirect"' href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651213782&amp;idx=1&amp;sn=6fab7af7962d65694a35e3f52abf39e4&amp;chksm=8b5f48b9bc28c1afbd0ec13b9eae9d8e08bf1a3c852d72e4c0c6420394fa362b1678d1a818ec&amp;token=1389154756&amp;lang=zh_CN&amp;scene=21#wechat_redirect" target="_blank" rel="noopener noreferrer" powered-by="xiumi.us" data-linktype="2"><section><p><strong>成纤维细胞（CAFs）</strong></p></section></a></section></section></section></section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><p><strong>04</strong></p></section></section><section><a title="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651214743&amp;idx=1&amp;sn=e8ff475ef8015a9222db5381416578d8&amp;chksm=8b5f54f8bc28ddee1f61b4fd9c1e4ba11dec78ca41a462e6b0b2c493864a95859ba6cf6f55d6&amp;token=1389154756&amp;lang=zh_CN&amp;scene=21#wechat_redirect" formlinkparm='"https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651214743&amp;idx=1&amp;sn=e8ff475ef8015a9222db5381416578d8&amp;chksm=8b5f54f8bc28ddee1f61b4fd9c1e4ba11dec78ca41a462e6b0b2c493864a95859ba6cf6f55d6&amp;token=1389154756&amp;lang=zh_CN&amp;scene=21#wechat_redirect"' href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651214743&amp;idx=1&amp;sn=e8ff475ef8015a9222db5381416578d8&amp;chksm=8b5f54f8bc28ddee1f61b4fd9c1e4ba11dec78ca41a462e6b0b2c493864a95859ba6cf6f55d6&amp;token=1389154756&amp;lang=zh_CN&amp;scene=21#wechat_redirect" target="_blank" rel="noopener noreferrer" powered-by="xiumi.us" data-linktype="2"><section><p><strong>单细胞空间转录组</strong></p></section></a></section></section></section></section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><p><strong>05</strong></p></section></section><section><a title="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651203828&amp;idx=1&amp;sn=c09dbafd10d170359061258913d3c7d6&amp;chksm=8b5f2f9bbc28a68de8996969b13f26c20c051fe30be2bfc409b3391e0764ac2d20bd09efcf2f&amp;scene=21#wechat_redirect" formlinkparm='"https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651203828&amp;idx=1&amp;sn=c09dbafd10d170359061258913d3c7d6&amp;chksm=8b5f2f9bbc28a68de8996969b13f26c20c051fe30be2bfc409b3391e0764ac2d20bd09efcf2f&amp;scene=21#wechat_redirect"' href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651203828&amp;idx=1&amp;sn=c09dbafd10d170359061258913d3c7d6&amp;chksm=8b5f2f9bbc28a68de8996969b13f26c20c051fe30be2bfc409b3391e0764ac2d20bd09efcf2f&amp;scene=21#wechat_redirect" target="_blank" rel="noopener noreferrer" powered-by="xiumi.us" data-linktype="2"><section><p><strong>肿瘤相关巨噬细胞（TAM）</strong></p></section></a></section></section></section></section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><p><strong>06</strong></p></section></section><section><a title="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651201615&amp;idx=1&amp;sn=154c456e092116f117e2dd478b05360b&amp;chksm=8b5f2720bc28ae36b5fe6679f26f02b4f4e5dbd40d131841bab2b5b2f750d9eb44755d762f0a&amp;scene=21#wechat_redirect" formlinkparm='"https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651201615&amp;idx=1&amp;sn=154c456e092116f117e2dd478b05360b&amp;chksm=8b5f2720bc28ae36b5fe6679f26f02b4f4e5dbd40d131841bab2b5b2f750d9eb44755d762f0a&amp;scene=21#wechat_redirect"' href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651201615&amp;idx=1&amp;sn=154c456e092116f117e2dd478b05360b&amp;chksm=8b5f2720bc28ae36b5fe6679f26f02b4f4e5dbd40d131841bab2b5b2f750d9eb44755d762f0a&amp;scene=21#wechat_redirect" target="_blank" rel="noopener noreferrer" powered-by="xiumi.us" data-linktype="2"><section><p><strong>细胞死亡</strong></p></section></a></section></section></section></section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><p><strong>07</strong></p></section></section><section><a title="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651214658&amp;idx=1&amp;sn=3ac27a20520442e202f7b39463c53e3a&amp;chksm=8b5f542dbc28dd3b83bfad73ae4876771060da87292aa6f0b4eec06420dc35191f1034a504e6&amp;token=1389154756&amp;lang=zh_CN&amp;scene=21#wechat_redirect" formlinkparm='"https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651214658&amp;idx=1&amp;sn=3ac27a20520442e202f7b39463c53e3a&amp;chksm=8b5f542dbc28dd3b83bfad73ae4876771060da87292aa6f0b4eec06420dc35191f1034a504e6&amp;token=1389154756&amp;lang=zh_CN&amp;scene=21#wechat_redirect"' href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651214658&amp;idx=1&amp;sn=3ac27a20520442e202f7b39463c53e3a&amp;chksm=8b5f542dbc28dd3b83bfad73ae4876771060da87292aa6f0b4eec06420dc35191f1034a504e6&amp;token=1389154756&amp;lang=zh_CN&amp;scene=21#wechat_redirect" target="_blank" rel="noopener noreferrer" powered-by="xiumi.us" data-linktype="2"><section><p><strong>耐药</strong></p></section></a></section></section></section></section><section powered-by="xiumi.us"><p><br></p></section><section powered-by="xiumi.us"><p><br></p></section><section powered-by="xiumi.us"><section><section powered-by="xiumi.us"><section><img data-ratio="1" data-src="https://mmbiz.qpic.cn/mmbiz_png/83gH9xsvaUchX8E4YI9WM9q7puwB7ZPGpNtjRWlDHJxWsN5KtO8qlTXPMhANyHhJRxJbFULYW7ULJNk65uUfmQ/640?wx_fmt=png" data-w="350" width="100%" src="https://mmbiz.qpic.cn/mmbiz_png/83gH9xsvaUchX8E4YI9WM9q7puwB7ZPGpNtjRWlDHJxWsN5KtO8qlTXPMhANyHhJRxJbFULYW7ULJNk65uUfmQ/640?wx_fmt=png"></section></section><section powered-by="xiumi.us"><section><p>课题设计 | 组学测序 |生信分析</p><p>培训工具 | 热点互动 | 资源互换</p></section></section></section></section><section powered-by="xiumi.us"><p><br></p></section><section powered-by="xiumi.us"><p><strong>撰稿小编｜</strong><strong><span>YHH</span></strong></p><p><strong>图文排版｜CY</strong></p><p><strong>文章转载请联系 | 15510012760（微信）</strong></p></section><section powered-by="xiumi.us"><p><br></p></section></section></section><p powered-by="xiumi.us"><br></p></section><p><mp-style-type data-value="10000"></mp-style-type></p></div>  
<hr>
<a href="https://mp.weixin.qq.com/s/kfyiEgziQGP313tJKaB8DA",target="_blank" rel="noopener noreferrer">原文链接</a>
